Thus, a small molecule approach based on an HCC tumor cell line that has lost ARID1A through promoter DNA hypermethylation combined with a phenotypic differential screen for candidate ARID1A mimetics may be the better approach, by far. This evidence concerns the gene ARID1A and neoplasm.